EGFR (epidermal growth factor receptor) is a protein found on the surface of cells. It plays an important role in regulating cell growth, division, and survival. Under normal conditions, EGFR helps cells grow in a controlled way through signaling pathways in the body. However, when a mutation occurs in the EGFR gene, this protein can become overactive, causing cells to grow uncontrollably and potentially leading to cancer, including lung cancer.
In lung cancer, especially non-small cell lung cancer (NSCLC) such as adenocarcinoma, EGFR mutations are among the most common genetic changes. Lung cancer with this mutation is referred to as EGFR-positive lung cancer. It is more frequently found in certain groups, such as women, non-smokers, or light smokers. However, not all NSCLC cases have EGFR mutations, as lung cancer can involve various other genetic alterations.
Interestingly, EGFR mutations are considered “targetable,” meaning they can be specifically treated with targeted therapy. These treatments work by blocking the signals that drive cancer cell growth, helping to slow down disease progression. Therefore, EGFR testing is important for lung cancer patients, as it helps doctors choose the most appropriate and effective treatment.
Why and How Does the EGFR Gene Mutate?
EGFR mutations are generally not inherited at birth but develop over time. Risk factors such as exposure to cigarette smoke, air pollution, and harmful environmental substances can increase the likelihood of these mutations. However, EGFR mutations are also commonly found in individuals who have never smoked, indicating that these changes can occur naturally without a clear trigger.
Certain patterns are observed in patients with EGFR mutations. They are more commonly found in women than men, and in patients with lung adenocarcinoma. These mutations are also more frequent in non-smokers or light smokers. Among younger patients, EGFR mutations are relatively common and can account for a significant portion of lung cancer cases.
Notably, EGFR mutations do not occur evenly across all populations. Individuals of Asian descent, particularly East Asians, have a higher incidence compared to other populations. This raises an important question: why are EGFR mutations more common in Asian patients?
Why Are EGFR Mutations More Common in Asian Patients?
EGFR mutations are more frequently found in lung cancer patients from Asian populations compared to others. In general, these mutations occur in about 15% of patients in the United States, but the rate can reach around 35% in East Asian populations. Some studies even report rates exceeding 50% in certain Asian countries.
In addition to ethnicity, EGFR mutations are more common in specific groups, including women, non-smokers or light smokers, and patients with lung adenocarcinoma. These characteristics are more commonly observed in Asian populations, which may partly explain the higher prevalence.
Although the exact cause is still being studied, genetic factors are believed to play a role. This is why EGFR testing is important, especially since many lung cancer cases are diagnosed at an advanced stage. By identifying EGFR mutations through tissue or blood tests, doctors can determine more precise and personalized treatment options.
The Role of EGFR in Targeted Therapy for Lung Cancer
EGFR mutations play a key role in determining treatment strategies for lung cancer, particularly NSCLC. These mutations cause cancer cells to continuously receive signals to grow, leading to faster disease progression. Because of their specific nature, EGFR mutations can be directly targeted in treatment.
For patients with EGFR mutations, doctors often recommend targeted therapy. These medications work by blocking abnormal EGFR activity, helping to slow cancer growth. In many cases, targeted therapy provides better outcomes than conventional chemotherapy, with fewer side effects. This makes EGFR testing an essential step before deciding on treatment.
KALGen Innolab, as a diagnostic laboratory, is committed to supporting early detection and management of lung cancer through comprehensive testing services. With advanced molecular diagnostic technology and experienced professionals, KALGen Innolab offers a range of molecular tests, including EGFR testing, to help determine the most suitable therapy for each patient. Accurate testing allows for more precise treatment and better outcomes.
Conclusion
EGFR is a protein that plays an important role in regulating cell growth. However, mutations in the EGFR gene can lead to uncontrolled cell growth and the development of lung cancer, particularly NSCLC. These mutations show certain patterns and are more commonly found in women, non-smokers, and Asian populations, although the exact causes are still being studied.
On the other hand, the presence of EGFR mutations opens the door to more targeted treatment options. With targeted therapy, treatment can directly address the underlying mechanism of cancer growth, making it more effective and generally associated with fewer side effects compared to conventional therapies. This highlights the importance of EGFR testing in determining the most appropriate treatment strategy.
Therefore, understanding EGFR and its role in lung cancer is essential for both early detection and treatment planning. Through proper testing, such as EGFR molecular testing, patients can receive more personalized and optimal care, improving their chances of successful treatment.
Consult your doctor about the need for EGFR testing, and ensure that the test is performed at a trusted laboratory such as KALGen Innolab, supported by advanced molecular technology to provide accurate and reliable results.
References
American Cancer Society. (2023). Lung cancer risk factors. https://www.cancer.org/cancer/types/lung-cancer/causes-risks-prevention/risk-factors.html
American Cancer Society. (2023). Targeted therapy for non-small cell lung cancer. https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html
American Lung Association. (2024). EGFR and lung cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr
da Cunha Santos, G., Shepherd, F. A., & Tsao, M. S. (2011). EGFR mutations and lung cancer. Annual Review of Pathology: Mechanisms of Disease, 6, 49–69. https://doi.org/10.1146/annurev-pathol-011110-130206
EGFR Resisters. (n.d.). About EGFR. https://egfrcancer.org/about-egfr/
LUNGevity Foundation. (n.d.). About EGFR-positive lung cancer. https://egfr.lungevity.org/egfr/about-egfr-positive-lung-cancer
Lynch, T. J., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. The New England Journal of Medicine, 350(21), 2129–2139. https://doi.org/10.1056/NEJMoa040938
National Cancer Institute. (n.d.). Non-small cell lung cancer treatment (PDQ®)–Patient version. https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
Rosell, R., et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC). The Lancet Oncology, 13(3), 239–246. https://doi.org/10.1016/S1470-2045(11)70393-X
.png)
